Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 19/20 | 0.71 |
| ▸ | PDE3A | Q14432 | 18/20 | 0.71 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30966600 | 1.00 | PDE3B (0.71) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL28615200 | 0.92 | PDE3B (0.61) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL28626629 | 0.92 | PDE3B (0.61) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL30966662 | 0.86 | PDE3B (0.56) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL22288567 | 0.86 | PDE3B (0.56) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL28628042 | 0.84 | PDE3B (0.57) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL20702638 | 0.83 | PDE3B (1.00) | PDE3BPDE3A | |
| SCHEMBL29842639 | 0.83 | PDE3B (1.00) | PDE3BPDE3A | |
| SCHEMBL28615454 | 0.83 | PDE3B (0.59) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL28616726 | 0.83 | PDE3B (0.64) | PDE3BPDE3APDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113348165-B | 1,2, 4-Triazin-3 (2H) -one compounds for the treatment of hyperproliferative diseases | 拜耳股份有限公司 | 2024-06-25 | — | — | CN | claimed |
| CN-113348165-A | 1,2, 4-triazin-3 (2H) -one compounds for the treatment of hyperproliferative diseases | 拜耳股份有限公司 | 2021-09-03 | — | — | CN | claimed |
| CN-113348165-B | 1,2, 4-Triazin-3 (2H) -one compounds for the treatment of hyperproliferative diseases | 拜耳股份有限公司 | 2024-06-25 | — | — | CN | disclosed |
| EP-3917915-A1 | 1,2,4-TRIAZIN-3(2H)-ONE COMPOUNDS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | Bayer Aktiengesellschaft (DE) | 2021-12-08 | — | — | EP | disclosed |
| US-20210353630-A1 | 1,2,4-TRIAZIN-3(2H)-ONE COMPOUNDS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-11-18 | — | — | US | disclosed |
| CN-113348165-A | 1,2, 4-triazin-3 (2H) -one compounds for the treatment of hyperproliferative diseases | 拜耳股份有限公司 | 2021-09-03 | — | — | CN | disclosed |
| WO-2020157194-A1 | 1,2,4-TRIAZIN-3(2H)-ONE COMPOUNDS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020157194-A1 | 1,2,4-TRIAZIN-3(2H)-ONE COMPOUNDS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210353630-A1 | 1,2,4-TRIAZIN-3(2H)-ONE COMPOUNDS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | CCNA1, CCNA2, CCNT2 | PDE3B 2576/4885PDE3A 2796/4885PDE4A 3071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.